COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Abivax annonce la fin du recrutement des patients dans le cadre de ses essais de phase 3 ABTECT dans le traitement de la rectocolite hémorragique (RCH) modérément à sévèrement active
Abivax annonce la fin du recrutement des patients pour ses essais de phase 3 ABTECT dans le traitement de la rectocolite hémorragique (RCH). Premiers résultats attendus T3 2025 -
COMMUNIQUÉ DE PRESSE
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Abivax completes enrollment for Phase 3 ABTECT Trials in patients with active ulcerative colitis. Top-line results expected in Q3 2025, NDA submission planned for H2 2026 -
-
COMMUNIQUÉ DE PRESSE
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
GENFIT announces filing of 2024 Universal Registration Document and Annual Report on Form 20-F with AMF and SEC, available for public viewing and download. Details of reports and company's focus on liver disease research and development highlighted -
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: aap Implantate AG: Postponement of the publication of the annual financial statements and consolidated financial statements for the financial year 2024
aap Implantate AG postpones the publication of its 2024 annual and consolidated financial statements due to auditor delay and resource constraints. New deadline set for June 2025
